Need professional-grade analysis? Visit stockanalysis.com
$18.57B
N/A
192
N/A
Nanjing Leads Biolabs Co Ltd (9887) trades on Hong Kong Stock Exchange in HKD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at HKD85.55, down 0.35% from the previous close.
Over the past year, 9887 has traded between a low of HKD48.40 and a high of HKD93.95. The stock has gained 27.5% over this period. It is currently 8.9% below its 52-week high.
Nanjing Leads Biolabs Co Ltd has a market capitalization of $18.57B.
Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialisation of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company's lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma, as well as LBL-034, LBL-033, and LBL-007. In addition, it develops LeadsBody platform, a portfolio of CD3 T-cell engagers that demonstrate anti-tumor efficacy and safety in preclinical/clinical studies; X-body platform, a 4-1BB/PD-L1 bispecific antibody. The company also develops antibody drugs for anti-tumor, autoimmune and infectious diseases and establishes tumor immunoassay. The company was founded in 2012 and is headquartered in Nanjing, China.
Side-by-side comparison against top Healthcare peers.